2m 2m 2m 2m 2m 2m 2m
ACTUATE THERAP (ACTU)
NASDAQ
$1.85+$0.02 (+1.37%)
Price as of Jun 03, 2026 6:35 PM EDT- $48.3MMarket Cap
- -80.02%1-Year Change
- BiotechnologyIndustry
ACTUATE THERAP (ACTU)
$1.85+$0.02 (+1.37%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -10.3M -44.89% | -18.7M N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 22.5M -10.59% | 25.2M N/A | |
Operating Profit | -22.5M -10.59% | -25.2M N/A | |
Interest Income | 287,710 +29.43% | 222,293 N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 287,710 +29.43% | 222,293 N/A | |
Total Nonoperating Income and Expense | 267,460 +112.59% | -2.1M N/A | |
Income before Taxes | -22.5M -10.59% | -25.2M N/A | |
Income Taxes | 800 0.00% | 800 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | N/A N/A | -27.3M N/A | |
Net Income from Continuing Operations Applicable to Common | N/A N/A | -27.3M N/A | |
Basic EPS and Net Income | -1.06 -67.48% | -3.26 N/A | |
Diluted EPS and Net Income | -1.06 -67.48% | -3.26 N/A | |
Basic Weighted Average Shares | 21.0M +151.07% | 8.4M N/A | |
Diluted Weighted Average Shares | 21.0M +151.07% | 8.4M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 13.2M +52.28% | 8.6M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 13.2M +52.28% | 8.6M N/A | |
Total Current Assets | 13.6M +48.17% | 9.2M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 392,491 +255.04% | 110,548 N/A | |
Total Assets | 14.0M +50.62% | 9.3M N/A | |
Income Taxes Payable | 3.2M -46.48% | 5.9M N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 5.7M -35.17% | 8.8M N/A | |
Total Long-Term Debt | 0 N/A | 0 N/A | |
Total Long-Term Liabilities | 404,991 -1.64% | 411,759 N/A | |
Total Liabilities | 6.1M -33.67% | 9.2M N/A | |
Retained Earnings | -154.6M +16.79% | -132.4M N/A | |
Total Stockholders Equity | N/A N/A | 104,186 N/A | |
Total Shares Outstanding | 23.2M +19.01% | 19.5M N/A | |
Cash Flow | |||
Cash from Operating Activities | -19.2M -12.07% | -21.8M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 23.7M -13.81% | 27.5M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 2.39 N/A | N/A N/A | |
Cash Ratio | 2.31 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow